Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
Open accessThe DOI matches its Crossref record; 22 of the 25 references it cites were found in a registry or an index.
Abstract
Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose reduction. Objective: Assess tildacerfont safety and efficacy. Design and Setting: Two Phase 2 open-label studies. Patients: Adults with 21OHD. Intervention: Oral tildacerfont 200 to 1000 mg once daily (QD) (n = 10) or 100 to 200 mg twice daily (n = 9 and 7) for 2 weeks (Study 1), and 400 mg QD (n = 11) for 12 weeks (Study 2). Main Outcome Measure: Efficacy was evaluated by changes from baseline at 8 am in adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) according to baseline A4 ≤ 2× upper limit of normal (ULN) or A4 > 2× ULN. Safety was evaluated using adverse events (AEs) and laboratory assessments. Results: In Study 1, evaluable participants with baseline A4 > 2× ULN (n = 11; 19-67 years, 55% female) had reductions from baseline in ACTH (−59.4% to −28.4%), 17-OHP (−38.3% to 0.3%), and A4 (−24.2% to −18.1%), with no clear dose response. In Study 2, participants with baseline A4 > 2× ULN (n = 5; 26-63 years, 40% female) had ~80% maximum mean reductions in biomarker levels. ACTH and A4 were normalized for 60% and 40%, respectively. In both studies, participants with baseline A4 ≤ 2× ULN maintained biomarker levels. AEs (in 53.6% of patients overall) included headache (7.1%) and upper respiratory tract infection (7.1%). Conclusions: For patients with 21OHD, up to 12 weeks of oral tildacerfont reduced or maintained key hormone biomarkers toward normal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Tildacerfont pharmacokinetics profiles (Study 201). In Cohort A [200, 600, or 1000 mg once daily (QD)], participants received tildacerfont at 10 pm. One participant in Cohort B and 1 participant in Cohort A at 1000 mg were discontinued prior to day 14 pharmacokinetic assessments. Participants who received twice daily (BID) dosing of tildacerfont received the dose at 10 am and 10 pm each day.](https://figures.cochat.ai/paper-figures/0a219b619e9b479ab36b01f0982c972a/tildacerfont-in-adults-with-classic-congenital-adrenal-hyperplasia-results-from-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In comparison with baseline in patients with poorly controlled disease, tildacerfont treatment induced average reductions of 74% for circulating levels of ACTH, 82% for levels of 17-OHP and 55% for levels of androstenedione.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [130]
In the citing paper
“By contrast, ACTH and androgen biomarkers remained stable for patients with good disease control; overall, tildacerfont was well tolerated130.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 10×
“Pathogenic variants of the CYP21A2 gene lead to dysfunction of the 21OH enzyme necessary for the biosynthesis of both corticosteroids and mineralocorticoids and to dysregulation across the hypothalamic-pituitary-adrenal axis (2,6).”
InfluentialSelf-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628 · cited 7×
“Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is an autosomal recessive disorder with an estimated incidence of 1:7000 to 1:18 000 live births worldwide (1-3), in which decreased adrenal biosynthesis of cortisol leads to accumulation of cortisol precursors, hyperplasia of the ad…”
BackgroundInfluentialSelf-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506 · cited 1×
“Patients with CAH suffer from not only adrenal insufficiency but also the consequences of chronic adrenalderived androgen excess including virilization, premature puberty, impaired fertility, acne, development of testicular adrenal rest tumors (TARTs) in males, and an impaired quality of life (5,8-10).”
BackgroundCongenital Adrenal Hyperplasia: Is there an Effect on Penile Growth?
Levy, J. B., & Husmann, D. A. (1996) · The Journal of Urology · doi:10.1097/00005392-199608001-00060 · Cited by 415
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344 · cited 1×
“Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is an autosomal recessive disorder with an estimated incidence of 1:7000 to 1:18 000 live births worldwide (1-3), in which decreased adrenal biosynthesis of cortisol leads to accumulation of cortisol precursors, hyperplasia of the ad…”
BackgroundCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341 · cited 1×
“A decrease in adrenal cortisol production impairs negative feedback on the hypothalamic-pituitary-adrenal axis, which increases production of corticotropin-releasing factor (CRF) and, consequently, adrenocorticotropic hormone (ACTH), the primary stimulus for cortisol and 19-carbon steroid production in the adrenal cor…”
BackgroundSelf-citationClinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 1×
“Patients with CAH suffer from not only adrenal insufficiency but also the consequences of chronic adrenalderived androgen excess including virilization, premature puberty, impaired fertility, acne, development of testicular adrenal rest tumors (TARTs) in males, and an impaired quality of life (5,8-10).”
BackgroundSelf-citation
Cited by
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationPhase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
“Trials of the CRF 1 antagonist tildacerfont, 42 gene therapy with BBP-631, and other agents targeting various levels of the hypothalamic-pituitary-adrenal axis are ongoing.”
Self-citationDisorders of Sex Development of Adrenal Origin
Finkielstain, G. P., Vieites, A., Bergadá, I., & Rey, R. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770782 · Cited by 67
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 46
Self-citationNewfield, R. S., Sarafoglou, K., Fechner, P. Y., Nokoff, N., Auchus, R. J., Vogiatzi, M. G., Jeha, G. S., Giri, N., Roberts, E., Sturgeon, J., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad270 · Cited by 39
Self-citation
Metadata
- Authors
- Sarafoglou, K., Barnes, C. N., Huang, M., Imel, E. A., Madu, I.-J., Merke, D. P., Moriarty, D., Nakhle, S., Newfield, R. S., Vogiatzi, M. G., & Auchus, R. J.
- Affiliations
- University of Minnesota (US)
- Seton Medical Center (US)
- Indiana University Indianapolis (US)
- Diabetes Associates Medical Group, Orange, CA, USA
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- Palm Medical Group, Las Vegas, NV, USA
- University of California San Diego (US)
- Children's Hospital of Philadelphia (US)
- University of Michigan (US)
- Corresponding author
- Barnes, Chris N
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-06-19
- Volume
- 106
- Issue
- 11
- Pages
- e4666-e4679
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8530725
- OpenAlex
- W3169341211
- Cited by
- 46
- References
- 25
- Citations by year
- 2026: 11 · 2025: 7 · 2024: 10 · 2023: 9 · 2022: 7 · 2021: 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
- Funders
- Spruce Biosciences, Inc.
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- classic congenital adrenal hyperplasia, 21-hydroxylase deficiency, CRF1 receptor antagonist, glucocorticoid dose reduction, androstenedione, ACTH, 17-hydroxyprogesterone, hyperandrogenism, adult patients, drug safety and efficacy, adverse events, headache, upper respiratory tract infection
- MeSH terms
- CRF Receptor, Type 1, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Aged, Androstenedione, Female, Follow-Up Studies, Humans, Male, Middle Aged, Biomarkers, Receptors, Corticotropin-Releasing Hormone, 17-alpha-Hydroxyprogesterone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. https://app.cochat.ai/papers/10.1210/clinem/dgab438
- The paper
- Sarafoglou, K., Barnes, C. N., Huang, M., Imel, E. A., Madu, I.-J., Merke, D. P., Moriarty, D., Nakhle, S., Newfield, R. S., Vogiatzi, M. G., & Auchus, R. J. (2021). Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.